-transparent.png){kind=logo}
In the present study, we determined the absolute and the percental numbers of T-lymphocytes in 113 patients with malignant melanomas, of whom 50 had metastases and 63 did not. The findings were compared to those in a control group of 22 persons. The patients with melanomas were divided up into clinical stages: stage I (primary tumour), II (metastases in the local lymph nodes), and stage III (systemic metastases). There was a statistically significant reduction of T-lymphocytes in all patients with melanomas, but there were no significant differences between the three stages. Therapy with DTIC did not lead to any major reduction in T-lymphocytes, possibly because of subsequent treatment with BCG. We found no clear correlation between the reduction of T-lymphocytes and an unfavourable prognosis.
R Klein, and
G R Krüger, and
K Sesterhenn
November 1978,
Cancer treatment reports,
R Klein, and
G R Krüger, and
K Sesterhenn
April 1997,
Experimental dermatology,
R Klein, and
G R Krüger, and
K Sesterhenn
April 2000,
Clinical cancer research : an official journal of the American Association for Cancer Research,
R Klein, and
G R Krüger, and
K Sesterhenn
January 1976,
Neoplasma,
R Klein, and
G R Krüger, and
K Sesterhenn
January 2005,
Medical oncology (Northwood, London, England),
R Klein, and
G R Krüger, and
K Sesterhenn
January 1977,
Voprosy onkologii,
R Klein, and
G R Krüger, and
K Sesterhenn
January 1978,
Voprosy onkologii,
R Klein, and
G R Krüger, and
K Sesterhenn
January 2002,
Glas. Srpska akademija nauka i umetnosti. Odeljenje medicinskih nauka,
R Klein, and
G R Krüger, and
K Sesterhenn
January 1982,
Journal of immunopharmacology,
R Klein, and
G R Krüger, and
K Sesterhenn
June 1980,
Ginekologia polska,
